SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-395591"
 

Search: onr:"swepub:oai:DiVA.org:uu-395591" > Understanding the I...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Hu, Yang,1989-Uppsala universitet,Institutionen för farmaceutisk biovetenskap (author)

Understanding the Influence of Nanocarrier-Mediated Brain Delivery on Therapeutic Performance Through Pharmacokinetic-Pharmacodynamic Modeling.

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • Elsevier BV,2019
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-395591
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-395591URI
  • https://doi.org/10.1016/j.xphs.2019.05.029DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Hammarlund-Udenaes, MargaretaUppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)marghamm (author)
  • Fridén, MarkusUppsala universitet,Institutionen för farmaceutisk biovetenskap,Department of Drug Metabolism and Pharmacokinetics, Early Respiratory, Inflammation and Autoimmunity, R&D Biopharmaceuticals, AstraZeneca R&D, Gothenburg, Sweden,tPKPD(Swepub:uu)mafri535 (author)
  • Uppsala universitetInstitutionen för farmaceutisk biovetenskap (creator_code:org_t)

Related titles

  • In:Journal of Pharmaceutical Sciences: Elsevier BV108:10, s. 3425-34330022-35491520-6017

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Hu, Yang, 1989-
Hammarlund-Udena ...
Fridén, Markus
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Pharmaceutical S ...
Articles in the publication
Journal of Pharm ...
By the university
Uppsala University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view